UK MHRA has issued positive scientific opinion enabling the drug’s inclusion on the Early Access to Medicines Scheme
Over 400 participants are being enrolled in the Phase I/II study after promising preclinical safety and immunogenicity data
Updated Date: Wed, 26 Aug 2020 00:00:00 EDT
Updated Date: Wed, 26 Aug 2020 00:00:00 EDT
Updated Date: Wed, 26 Aug 2020 00:00:00 EDT
Updated Date: Wed, 26 Aug 2020 00:00:00 EDT
Updated Date: Wed, 26 Aug 2020 00:00:00 EDT
CDC sets its sights on November COVID-19 vaccine deliveries: report esagonowsky Wed, 09/02/2020 – 15:01
A new antibacterial agent that has been engineered to essentially hide from the human immune system may treat […]
